

Routine field studies of the effectiveness of presently licensed influenza vaccines that use virus-confirmed endpoints are needed for all age groups. Because placebo-controlled efficacy studies are not feasible for licensed vaccines, innovative approaches to measurement of vaccine effectiveness will be important. Moreover, studies of new technology vaccines, if undertaken in countries with universal vaccination recommendations, will probably need comparison groups that receive licensed vaccines and are powered to show superiority rather than non-inferiority.